Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP

Basit Öğe Kaydı
dc.contributor.authorBodur, Hatice
dc.contributor.authorAtaman, Sebnem
dc.contributor.authorBugdayci, Derya Soy
dc.contributor.authorRezvani, Aylin
dc.contributor.authorNas, Kemal
dc.contributor.authorUzunca, Kaan
dc.contributor.authorEmlakcioglu, Emel
dc.date.accessioned2020-03-26T18:24:38Z
dc.date.available2020-03-26T18:24:38Z
dc.date.issued2012
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractA web-based application patient follow-up program was developed to create a registry of patients with ankylosing spondylitis (AS) by the Turkiye Romatizma Arastirma Savas Dernegi (TRASD) AS Study Group. This study describes the methodological background and patient characteristics. The patient follow-up program is a web-based questionnaire, which contains sections on socio-demographic data, anamnesis, personal and family history, systemic and musculoskeletal examination, laboratory and imaging data and treatment. Between October 1, 2007 and February 28, 2009, 1,381 patients from 41 centers were included in the registry (1,038 males [75.2%]; mean age 39.5 +/- A 10.7 years). Mean disease duration was 12.1 +/- A 8.5 years, and mean time from initial symptom to diagnosis was 5 +/- A 6.8 years (median 2 years). HLA-B27 positivity was detected in 73.7% of 262 patients tested. Manifestations of extraarticular involvement were anterior uveitis (13.2%), psoriasis and other skin and mucous membrane lesions (6%) and inflammatory bowel disease (3.8%). The prevalence of peripheral arthritis was 11.2%. In 51.7% of patients, the Bath AS Disease Activity Index was a parts per thousand yen4. But since our patients consisted of the ones with more severe disease who referred to the tertiary centers and needed a regular follow-up, they may not represent the general AS population. Disease-modifying anti-rheumatic drugs were being used by 41.9% of patients, with 16.4% using anti-TNF agents. TRASD-IP (Izlem Programi: Follow-up program) is the first AS registry in Turkey. Such databases are very useful and provide a basis for data collection from large numbers of subjects. TRASD-IP gives information on the clinical and demographic profiles of patients, and the efficacy and safety of anti-TNF drugs, examines the impact on quality of life, and provides real-life data that may be used in cost-effectiveness analyses.en_US
dc.description.sponsorshipWyeth/Pfizer CompanyWyethen_US
dc.description.sponsorshipThe authors express their gratitude to all members of TRASD AS Study group for their cooperation and to Wyeth/Pfizer Company for the sponsorship. The authors declare that they have no conflict of interest.en_US
dc.identifier.doi10.1007/s00296-010-1599-7en_US
dc.identifier.endpage176en_US
dc.identifier.issn0172-8172en_US
dc.identifier.issn1437-160Xen_US
dc.identifier.issue1en_US
dc.identifier.pmid20711591en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage169en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s00296-010-1599-7
dc.identifier.urihttps://hdl.handle.net/20.500.12395/27881
dc.identifier.volume32en_US
dc.identifier.wosWOS:000299007300027en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGER HEIDELBERGen_US
dc.relation.ispartofRHEUMATOLOGY INTERNATIONALen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAnkylosing spondylitisen_US
dc.subjectPatient registryen_US
dc.titleDescription of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IPen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu